Lionco Pharmaceutical Group Co.,Ltd.

SHSE:603669 주식 보고서

시가총액: CN¥4.5b

Lionco Pharmaceutical GroupLtd 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ling Ping Tao

최고 경영자

CN¥660.0k

총 보상

CEO 급여 비율n/a
CEO 임기no data
CEO 소유권6.8%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간데이터 없음

최근 관리 업데이트

Recent updates

Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Nov 06
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Oct 29
Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

May 10
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

Mar 12
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

CEO

Ling Ping Tao (54 yo)

no data

테뉴어

CN¥660,000

보상

Ms. Ling Ping Tao is General Manager of Lionco Pharmaceutical Group Co.,Ltd. and serves as its Chairman of the Board.